Slow viral dynamics of hepatitis C virus genotype 4

被引:26
作者
Halfon, P
Neumann, AU
Bourlière, M
Rieu, A
Chadapaud, S
Khiri, H
Ouzan, D
机构
[1] Dept Virol, Alphabio Lab, Marseille, France
[2] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel
[3] St Joseph Hosp, Marseille, France
[4] Chalucet Hosp, Toulon, France
[5] Arnault Tzanck Inst, Paris, France
[6] Dept Internal Med, Paris, France
关键词
genotype; 4; hepatitis C virus; interferon alpha; kinetic; viral load;
D O I
10.1046/j.1365-2893.2003.00433.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients infected with hepatitis C virus genotype 4 (HCV-4) respond to interferon alpha (IFN) as poorly as those infected with genotype 1. However, there is no information on the viral dynamics of HCV-4. Interferon-ribavirin treatment was administered to untreated patients infected with HCV-4. Viral load was assessed with Versant 3.0. Viral dynamics parameters were estimated based on the bi-phasic model for HCV during IFN treatment. Viral kinetics of HCV-4 follow a bi-phasic decline pattern also. The mean effectiveness of IFN in blocking production of HCV-4 was a decline of 77.8% during the first day of treatment. The half-life of free virions was estimated at 3.5 h and that of infected cells from 1.9 to over 70 days. The viral dynamics parameters of HCV-4 appear similar to those of HCV-1 and slower than those of HCV-2. HCV-4 infected patients should be grouped with those with HCV-1 when therapeutic schemes are considered in relation to genotype.
引用
收藏
页码:351 / 353
页数:3
相关论文
共 16 条
[1]   GENETIC-HETEROGENEITY OF HEPATITIS-C VIRUS - QUASI-SPECIES AND GENOTYPES [J].
BUKH, J ;
MILLER, RH ;
PURCELL, RH .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :41-63
[2]   Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene) [J].
Halfon, P ;
Trimoulet, P ;
Bourliere, M ;
Khiri, H ;
de Lédinghen, V ;
Couzigou, P ;
Feryn, JM ;
Alcaraz, P ;
Renou, C ;
Fleury, HJA ;
Ouzan, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (05) :1771-1773
[3]  
Herrmann E, 2000, ANTIVIR THER, V5, P85
[4]  
Lam NP, 1997, HEPATOLOGY, V26, P1692
[5]  
Layden T J, 1999, Clin Liver Dis, V3, P793, DOI 10.1016/S1089-3261(05)70239-7
[6]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[7]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[8]   Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Davidian, M ;
Wiley, TE ;
Mika, BP ;
Perelson, AS ;
Layden, TJ .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01) :28-35
[9]   Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Gretch, DR ;
Wiley, TE ;
Layden, TJ ;
Perelson, AS .
SCIENCE, 1998, 282 (5386) :103-107
[10]  
Perelson Alan S., 1999, American Journal of Medicine, V107, p49S